Verapamil is a slow calcium channel blocker that has been in clinical use for almost 20 years as an antiarrhythmic agent. It also has an antianginal action,' but inconsistent results have been obtained in clinical trials owing to insufficient dosage.2 We found that the drug produced a significant decrease in the number of anginal attacks and the consumption of glyceryl trinitrate with improvement in exercise tolerance and ST changes when used in a dose of 360 mg daily. 3 We have now compared the potency and mode of action of verapamil with those of propranolol, a standard beta-adrenergicreceptor-blocking drug, using fixed high doses of each.
Patients, methods, and results
Twenty-two patients (age range 41-69 years) with confirmed chronic stable angina completed a double-blind cross-over trial designed as a direct objective comparison between verapamil and propranolol in which exercise data were measured.4 After a two-week run-in period when they took a placebo the patients were treated over four-week periods with verapamil 120 mg thrice daily or propranolol 80 mg thrice daily (at 0800, 1400, and 2000).
Exercise tests on a treadmill (Quinton) were repeated after the placebo and each treatment period (90-150 minutes after the last dose of the drug).
The Four patients became free of angina with propranolol and 10 with verapamil. Propranolol improved the exercise time by 40 %O; its primary effect appeared to be to reduce heart rate (resting heart rate was reduced by 26O" and maximum exercise heart rate by 23°). The heart rate recovery was not altered. The maximum ST-segment depression corrected for exercise time was significantly reduced (p <0 001). Verapamil had a different effect: it reduced the resting heart rate by only 6 5 O and the maximal exercise heart rate by 3 %o. The heart rate recovery was not altered. The maximum ST-segment change remained the same. The exercise time, however, increased by 66 %X, and the maximum heart rate and ST depression-seen during placebo treatment at 5 5 minutes-now occurred at 9-1 minutes. These figures suggest an improved exercise tolerance with no adverse effect on ischaemia. ST-segment recovery was also unchanged.
Comment
Verapamil has little negative chronotropic effect but improves exercise tolerance more than propranolol, probably because of decreased coronary vasomotion and improved myocardial oxygen consumption. On the other hand, propranolol seems to act predominantly through its negative chronotropic effect. These observations are important to clinicians. Patients with resting bradycardia and a poor chronotropic response to exercise would be expected to respond better to verapamil, while those with resting tachycardia and an appreciable chronotropic response to exercise would respond better to propranolol. These observations have obvious practical implications in choosing treatment rationally.
VBS is supported by a grant from the British Heart Foundation. monocytes 2 "). Direct aspiration of the shunt reservoir yielded clear cerebrospinal fluid, which on examination showed white cell count 0-01 x 109/1, protein 0-35 g/l, and glucose 3 8 mmol/l (68 mg/100 ml). 
Ventriculoatrial shunt colonisation has been described as "early" when the symptoms appear two or three months after operation and "late" when the patient remains symptom free for several months or even years after operation.3 The early cases have been shown to originate at operation, when bacteria normally present on the skin become implanted at the site of the operation and subsequently colonise the shunt. Late colonisation has been attributed to ascending colonisation from the tip of the atrial catheter after transient bacteremia.4 Both types of colonisation have recently been shown to have the same aetiology, however, the onset of bacterial colonisation of the shunt occurring at operation.3
Most cases of brucellosis in man result from direct contact with sick animals or ingestion of unpasteurised milk from infected animals. Our patient had animal contacts in an area where bovine brucellosis is a problem. He had also taken unpasteurised cows' milk on several occasions. The infecting organism appears to have entered the shunt and the cerebrospinal fluid from the blood stream after septicaemia caused by Br abortus.
Treatment in shunt colonisation consists of removing the shunt and replacing it when the cerebrospinal fluid is sterile. In brucellosis the treatment of choice is tetracycline. Our patient was initially given antibiotics directed against the organism (Staph albus) most commonly responsible for shunt colonisation, and the infected shunt was subsequently removed. By the time culture results had become available the cerebrospinal fluid and blood were sterile and he had shown a remarkable clinical recovery without having been treated specifically for brucellosis. Ketotifen overdose: surveillance of the toxicity of a new drug Self-poisoning is often with drugs that have been selected indiscriminately by the patient with no knowledge of their effects.' Hence doctors may be faced with overdoses of new and unfamiliar compounds for which there is little information on the likely symptoms or the most appropriate treatment. Such advice as can be offered is usually based on extrapolation from toxicity studies in animals and from clinical experience with other, similar drugs, but the value of such information is questionable.
A recent example of this was provided by the introduction of the antiasthmatic drug ketotifen (Zaditen, Sandoz Limited), a selective mast-cell stabiliser with many features of an antihistamine. Through the National Poisons Information Service effective surveillance of the acute toxicity of a new compound can be monitored from the first recorded cases. Within four months of ketotifen being marketed eight cases of overdose had been reported and a reasonable estimate could be made of the acute toxicity of the drug in man.
Summary of cases
The table gives brief details of the eight cases. Gastric lavage was used in six patients, one (case 5) was given syrup of ipecacuanha, and in case 6 no attempt was made to empty the stomach. All eight patients received supportive treatment only and made a full recovery within 12 hours of admission. Toxicological screens were performed at the poisons unit and plasma ketotifen concentrations measured by Sandoz, Basle Limited, using mass spectrometry after gas chromatographic separation. Monitoring the clinical presentation and outcome in alleged drug overdosage can provide useful information,3 but before the toxicity of a compound can be assessed with any certainty it is important to prove that the drug concerned was present in toxic amounts. Therapeutic plasma concentrations of ketotifen range from 1 to 4 mg/l. Thus case 3 is typical of many patients who patently did not take the dose of the drug which was claimed, while in case 2 the patient had definitely
